<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.nature.com/articles/s41591-023-02565-4">Original</a>
    <h1>MDMA-assisted therapy for PTSD: A randomized, placebo-controlled phase 3 trial</h1>
    
    <div id="readability-page-1" class="page"><div>
                <section data-title="Main"><div id="Sec1-section"><h2 id="Sec1">Main</h2><div id="Sec1-content"><p>Post-traumatic stress disorder (PTSD) is a serious neuropsychiatric condition affecting approximately 5% of the US population each year<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="US Department of Veteran Affairs. PTSD: National Center for PTSD. How common is PTSD in adults? (
                https://www.ptsd.va.gov/understand/common/common_adults.asp
                
              )." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR1" id="ref-link-section-d290364475e874">1</a></sup>. Managing PTSD is particularly complicated in individuals experiencing the dissociative subtype of PTSD, recurrent exposure to trauma and comorbidities, such as mood disorders and alcohol and substance use disorders<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="de Silva, U., Glover, N. &amp; Katona, C. Prevalence of complex post-traumatic stress disorder in refugees and asylum seekers: systematic review. BJPysch Open 7, e194 (2021)." href="#ref-CR2" id="ref-link-section-d290364475e878">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="de Castro Longo, M. S. et al. Comorbidity in post-traumatic stress disorder: a population-based study from the two largest cities in Brazil. J. Affect. Disord. 263, 715–721 (2020)." href="#ref-CR3" id="ref-link-section-d290364475e878_1">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Hill, S. B. et al. Dissociative subtype of posttraumatic stress disorder in women in partial and residential levels of psychiatric care. J. Trauma Dissociation 21, 305–318 (2020)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR4" id="ref-link-section-d290364475e881">4</a></sup>. Together, these factors are associated with symptom exacerbation, treatment resistance and treatment discontinuation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="de Castro Longo, M. S. et al. Comorbidity in post-traumatic stress disorder: a population-based study from the two largest cities in Brazil. J. Affect. Disord. 263, 715–721 (2020)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR3" id="ref-link-section-d290364475e885">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Roberts, N. P., Lotzin, A. &amp; Schäfer, I. A systematic review and meta-analysis of psychological interventions for comorbid post-traumatic stress disorder and substance use disorder. Eur. J. Psychotraumatol. 13, 2041831 (2022)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR5" id="ref-link-section-d290364475e888">5</a></sup>. Trauma-focused psychotherapies are the gold standard treatment for PTSD. However, many individuals have persisting symptomology, and dropout rates are high<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Lewis, C., Roberts, N. P., Gibson, S. &amp; Bisson, J. I. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur. J. Psychotraumatol. 11, 1709709 (2020)." href="#ref-CR6" id="ref-link-section-d290364475e892">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Steenkamp, M. M., Litz, B. T., Hoge, C. W. &amp; Marmar, C. R. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA 314, 489–500 (2015)." href="#ref-CR7" id="ref-link-section-d290364475e892_1">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Mavranezouli, I. et al. Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol. Med. 50, 542–555 (2020)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR8" id="ref-link-section-d290364475e895">8</a></sup>. Although the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine are FDA approved for treating PTSD, 35–47% of individuals do not respond to treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Alexander, W. Pharmacotherapy for post-traumatic stress disorder in combat veterans: focus on antidepressants and atypical antipsychotic agents. Pharm. Ther. 37, 32 (2012)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR9" id="ref-link-section-d290364475e899">9</a></sup>. More effective, therapeutic interventions are needed to address the immense individual, societal and economic burdens of PTSD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Davis, L. L. et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective. J. Clin. Psychiatry 83, 21m14116 (2022)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR10" id="ref-link-section-d290364475e904">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Couette, M., Mouchabac, S., Bourla, A., Nuss, P. &amp; Ferreri, F. Social cognition in post-traumatic stress disorder: a systematic review. Br. J. Clin. Psychol. 59, 117–138 (2020)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR11" id="ref-link-section-d290364475e907">11</a></sup>.</p><p>Mounting evidence supports substituted phenethylamine 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) as a treatment for PTSD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e914">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacol. (Berl.) 236, 2735–2745 (2019)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR13" id="ref-link-section-d290364475e917">13</a></sup>. MDMA, an entactogen that promotes monoamine reuptake inhibition and release (primarily by inducing conformational change of pre-synaptic transporters<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Nichols, D. E. Entactogens: how the name for a novel class of psychoactive agents originated. Front. Psychiatry 13, 863088 (2022)." href="#ref-CR14" id="ref-link-section-d290364475e921">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Mayer, F. P. et al. Serotonin-releasing agents with reduced off-target effects. Mol. Psychiatry 28, 722–732 (2023)." href="#ref-CR15" id="ref-link-section-d290364475e921_1">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sandtner, W. et al. Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol. Pharmacol. 89, 165 (2016)." href="#ref-CR16" id="ref-link-section-d290364475e921_2">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Sáez-Briones, P. &amp; Hernández, A. MDMA (3,4-methylenedioxymethamphetamine) analogues as tools to characterize MDMA-like effects: an approach to understand entactogen pharmacology. Curr. Neuropharmacol. 11, 521–534 (2013)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR17" id="ref-link-section-d290364475e924">17</a></sup>), effectively modulates fear memory reconsolidation, enhances fear extinction and promotes openness and prosocial behavior<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Feduccia, A. A. &amp; Mithoefer, M. C. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog. Neuropsychopharmacol. Biol. Psychiatry 84, 221–228 (2018)." href="#ref-CR18" id="ref-link-section-d290364475e928">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kamilar-Britt, P. &amp; Bedi, G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci. Biobehav. Rev. 57, 433–446 (2015)." href="#ref-CR19" id="ref-link-section-d290364475e928_1">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Vizeli, P. et al. Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front. Pharm. 13, 906639 (2022)." href="#ref-CR20" id="ref-link-section-d290364475e928_2">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Maples-Keller, J. L. et al. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J. Psychopharmacol. 36, 368–377 (2022)." href="#ref-CR21" id="ref-link-section-d290364475e928_3">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Hysek, C. M. et al. MDMA enhances emotional empathy and prosocial behavior. Soc. Cogn. Affect. Neurosci. 9, 1645–1652 (2014)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR22" id="ref-link-section-d290364475e931">22</a></sup>. Several phase 2 trials indicated that MDMA-AT has an acceptable risk–benefit profile in individuals with PTSD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacol. (Berl.) 236, 2735–2745 (2019)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR13" id="ref-link-section-d290364475e935">13</a></sup>. A pivotal phase 3 study (MAPP1) showed that MDMA-AT was generally well tolerated and met the trial’s primary and secondary endpoints of reduced PTSD symptom severity and decreased functional impairment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e939">12</a></sup>.</p><p>Due to disparities in trauma exposure, gender-diverse and transgender individuals, ethnoracial minorities, first responders, military personnel, veterans and victims of chronic sexual abuse have a disproportionately higher risk of developing PTSD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="de Silva, U., Glover, N. &amp; Katona, C. Prevalence of complex post-traumatic stress disorder in refugees and asylum seekers: systematic review. BJPysch Open 7, e194 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR2" id="ref-link-section-d290364475e946">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Brooks Holliday, S. et al. The association between discrimination and PTSD in African Americans: exploring the role of gender. Ethn. Health 25, 717–731 (2020)." href="#ref-CR23" id="ref-link-section-d290364475e949">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Goldstein, R. B. et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc. Psychiatry Psychiatr. Epidemiol. 51, 1137–1148 (2016)." href="#ref-CR24" id="ref-link-section-d290364475e949_1">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Zimmerman, M., Benjamin, I. &amp; Seijas-Rodriguez, C. Psychiatric diagnoses among transgender and gender diverse patients compared to cisgender patients. J. Clin. Psychiatry 83, 21m14062 (2022)." href="#ref-CR25" id="ref-link-section-d290364475e949_2">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Herman, J. L. Complex PTSD: a syndrome in survivors of prolonged and repeated trauma. J. Trauma Stress 5, 377–391 (1992)." href="#ref-CR26" id="ref-link-section-d290364475e949_3">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Schein, J. et al. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. Curr. Med Res. Opin. 37, 2151–2161 (2021)." href="#ref-CR27" id="ref-link-section-d290364475e949_4">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Lewis-Schroeder, N. F. et al. Conceptualization, assessment, and treatment of traumatic stress in first responders: a review of critical issues. Harv. Rev. Psychiatry 26, 216–227 (2018)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR28" id="ref-link-section-d290364475e952">28</a></sup>. However, these diverse populations are historically underrepresented in clinical trials<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Williams, C. P., Senft Everson, N., Shelburne, N. &amp; Norton, W. E. Demographic and health behavior factors associated with clinical trial invitation and participation in the United States. JAMA Netw. Open 4, e2127792 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR29" id="ref-link-section-d290364475e956">29</a></sup>. Here we report the results of MAPP2, the second, confirmatory phase 3 study that extends the findings of MAPP1 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e960">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Ching, T. H. et al. MDMA-assisted therapy for posttraumatic stress disorder: a pooled analysis of ethnoracial differences in efficacy and safety from two phase 2 open-label lead-in trials and a phase 3 randomized, blinded placebo-controlled trial. J. Psychopharmacol. 36, 974–986 (2022)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR30" id="ref-link-section-d290364475e963">30</a></sup>) in an ethnoracially diverse population with moderate to severe PTSD (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">1</a>).</p></div></div></section><section data-title="Results"><div id="Sec2-section"><h2 id="Sec2">Results</h2><div id="Sec2-content"><h3 id="Sec3">Demographics and baseline characteristics</h3><p>Participants were recruited from 21 August 2020 to 18 May 2022 (last participant visit on 2 November 2022). Overall, 324 individuals were screened, and 121 were enrolled. Of these, 17 individuals did not meet enrollment confirmation after initiation of preparation therapy, and 104 were confirmed for randomization: 53 were assigned to MDMA-AT and 51 to placebo with therapy (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Fig1">1</a>). Ninety-four participants completed the study, and nine discontinued (<i>n</i> = 1 MDMA-AT; <i>n</i> = 8 placebo with therapy) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Fig1">1</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">3</a>).</p><div data-test="figure" data-container-section="figure" id="figure-1" data-title="CONSORT diagram."><figure><figcaption><b id="Fig1" data-test="figure-caption-text">Fig. 1: CONSORT diagram.</b></figcaption><div><div><a data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="https://jvns.ca/articles/s41591-023-02565-4/figures/1" rel="nofollow"><picture><img aria-describedby="Fig1" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-023-02565-4/MediaObjects/41591_2023_2565_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="497"/></picture></a></div><p>CONSORT diagram, indicating participant numbers and disposition throughout the course of the trial. Endpoint assessments (T1, T2, T3 and T4) of CAPS-5 and SDS were conducted after each experimental session. <sup>a</sup>The number of individuals after an initial phone screening who gave informed consent. <sup>b</sup>Other reasons for exclusion could include withdrawal of consent, adverse event or death, discontinuation of treatment by investigator, lack of therapeutic rapport and illness or lost to follow-up. <sup>c</sup>One participant in the placebo with therapy group completed the study but had missing item-level data on the final CAPS-5 assessment, and the final assessment was not included in the analysis of the de jure estimand. AE, adverse event; ITT, intention to treat; mITT, modified intention to treat; T, time of endpoint assessment; T1, baseline; T2, after experimental session 1; T3, after experimental session 2; T4, 6–8 weeks after experimental session 3 (18 weeks after baseline).</p></div></figure></div><p>Baseline characteristics were generally similar between groups (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Tab1">1</a>). In total, 74 of 104 (71.2%) participants were assigned female sex at birth, with a higher proportion in the placebo with therapy group (42/51, 82.4%) than the MDMA-AT group (32/53, 60.4%). Participants were ethnically and racially diverse: 35 of 104 (33.7%) participants identified their race as other than White, and 28 of 104 (26.9%) identified their ethnicity as Hispanic/Latino. The mean (s.d.) duration of PTSD was 16.2 (13.3) years. The mean (s.d.) Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score at baseline was 39.0 (6.6) and was similar between groups. Overall, 28 of 104 (26.9%) and 76 of 104 (73.1%) participants had moderate and severe PTSD, respectively; the dissociative subtype was present in 24 of 104 (23.1%) participants.</p><div data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption><b id="Tab1" data-test="table-caption">Table 1 Demographics and clinical characteristics of participants at baseline</b></figcaption></figure></div><h3 id="Sec4">Primary outcomes</h3><p>MDMA-AT significantly attenuated PTSD symptomology versus placebo with therapy, as measured by a reduction in CAPS-5 total severity score from baseline to 18 weeks. Mixed models for repeated measures (MMRM) analysis of the de jure estimand showed a least squares (LS) mean (95% confidence interval (CI)) change of −23.7 (−26.94, −20.44) for MDMA-AT versus −14.8 (−18.28, −11.28) for placebo with therapy (treatment difference: −8.9 (−13.70, −4.12), <i>P</i> &lt; 0.001; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Fig2">2a</a>). The Cohen’s <i>d</i> effect size of MDMA-AT versus placebo with therapy was <i>d</i> = 0.7; the within-group effect sizes were <i>d</i> = 1.95 for MDMA-AT and <i>d</i> = 1.25 for placebo with therapy. MMRM analysis of the de facto estimand revealed an LS mean change (95% CI) in CAPS-5 scores of −23.7 (−26.97, −20.47) for the MDMA-AT group versus −14.8 (−18.24, −11.33) for the placebo with therapy group (<i>P</i> &lt; 0.001).</p><div data-test="figure" data-container-section="figure" id="figure-2" data-title="Measures of efficacy in the MDMA-AT and placebo with therapy groups."><figure><figcaption><b id="Fig2" data-test="figure-caption-text">Fig. 2: Measures of efficacy in the MDMA-AT and placebo with therapy groups.</b></figcaption><div><div><a data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="https://jvns.ca/articles/s41591-023-02565-4/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-023-02565-4/MediaObjects/41591_2023_2565_Fig2_HTML.png?as=webp"/><img aria-describedby="Fig2" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-023-02565-4/MediaObjects/41591_2023_2565_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="972"/></picture></a></div><div data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>, LS mean change (±s.e.m.) in CAPS-5 total severity score from baseline to after session 3 (primary outcome) for placebo with therapy (<i>n</i> = 50) versus MDMA-AT (<i>n</i> = 53, <i>P</i> &lt; 0.001, Cohen’s <i>d</i> = 0.7). <b>b</b>, LS mean change (±s.e.m.) in SDS total score from baseline to after session 3 (key secondary outcome) for placebo with therapy (<i>n</i> = 50) versus MDMA-AT (<i>n</i> = 53, <i>P</i> = 0.03, Cohen’s <i>d</i> = 0.4).</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM3">Source data</a></p></div></div></figure></div><h3 id="Sec5">Secondary outcomes</h3><p>MDMA-AT significantly mitigated clinician-rated functional impairment, as measured by a reduction in the Sheehan Disability Scale (SDS) from baseline. MMRM analysis of the de jure estimand revealed that the LS mean change (95% CI) in SDS total scores was −3.3 (−4.03, −2.60) with MDMA-AT versus −2.1 (−2.89, −1.33) with placebo with therapy (treatment difference: −1.20 (−2.26, −0.14); <i>P</i> = 0.03, <i>d</i> = 0.4; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Fig2">2b</a>). Improvements were observed across all domains, including family life, social life and work life (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">4</a>).</p><h3 id="Sec6">Exploratory outcomes</h3><p>In the MDMA-AT group, 45 of 52 (86.5%) participants were responders with a clinically meaningful improvement at 18 weeks after baseline, defined as a ≥10-point reduction in CAPS-5 total severity score, versus 29 of 42 (69.0%) in the placebo with therapy group (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Fig3">3</a>). By study end, 37 of 52 (71.2%) participants in the MDMA-AT group no longer met DSM-5 criteria for PTSD versus 20 of 42 (47.6%) participants in the placebo with therapy group. Furthermore, 24 of 52 (46.2%) participants in the MDMA-AT group and nine of 42 (21.4%) participants in the placebo with therapy group met remission criteria (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Fig3">3</a>). The net number of participants needed to treat for each responder analysis group was as follows: responder, six; non-responder, six; loss of diagnosis, four; remission, four.</p><div data-test="figure" data-container-section="figure" id="figure-3" data-title="Treatment response and remission in the MDMA-AT (n = 53) and placebo with therapy (n = 50) groups."><figure><figcaption><b id="Fig3" data-test="figure-caption-text">Fig. 3: Treatment response and remission in the MDMA-AT (<i>n</i> = 53) and placebo with therapy (<i>n</i> = 50) groups.</b></figcaption><div><div><a data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="https://jvns.ca/articles/s41591-023-02565-4/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-023-02565-4/MediaObjects/41591_2023_2565_Fig3_HTML.png?as=webp"/><img aria-describedby="Fig3" src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-023-02565-4/MediaObjects/41591_2023_2565_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="205"/></picture></a></div><div data-test="bottom-caption" id="figure-3-desc"><p>A ≥10-point reduction in CAPS-5 total severity score was considered to be clinically meaningful. Responders (≥10-point reduction from baseline), loss of diagnosis (≥10-point reduction from baseline and no longer meeting PTSD diagnostic criteria) and remission (loss of diagnosis and CAPS-5 total severity score of 11 or less) were tracked in both groups as a percentage of participants. Non-responders were defined as any CAPS-5 total severity score change &lt;10-point reduction from baseline.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM4">Source data</a></p></div></div></figure></div><p>Covariate analyses demonstrated similar responses to treatment regardless of disease severity, risk of hazardous alcohol or substance use disorder, severe adverse childhood experiences or dissociative subtype PTSD. The only measured exploratory covariate with a significant interaction with treatment was lifetime history of SSRI use, which was associated with improved efficacy of MDMA-AT (<i>P</i> = 0.02; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">5</a>). Covariates significantly impacting the main effect were sex assigned at birth and baseline Beck Depression Inventory (BDI)-II score; female sex assigned at birth and baseline BDI-II score ≥23 were both associated with improved outcomes irrespective of treatment assignment (<i>P</i> &lt; 0.05).</p><p>A blinding survey conducted at study termination showed that 33 of 44 (75.0%) participants in the placebo with therapy group were certain or thought they received placebo, whereas nine of 44 (20.5%) participants inaccurately thought that they received MDMA, and two of 44 (4.5%) participants could not tell. In the MDMA-AT group, 49 of 52 (94.2%) participants were certain or thought that they received MDMA; one of 52 (1.9%) participants inaccurately thought that they received placebo; and two of 52 (3.8%) participants could not tell (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">6</a>). When asked for the reason for their belief in treatment assignment, most participants in the MDMA-AT group reported attributing their response on the blinding survey to experiencing positive mental or emotional effect (45/52 (86.5%)) and positive physical effect (29/52 (55.8%)), whereas most of the participants in the placebo with therapy group reported experiencing no effect (28/44 (63.6%)).</p><h3 id="Sec7">Safety</h3><p>Most participants (102/104, 98.1%) experienced at least one treatment-emergent adverse event (TEAE) during the study (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Tab2">2</a>); seven experienced a severe TEAE (MDMA-AT, <i>n</i> = 5 (9.4%); placebo with therapy, <i>n</i> = 2 (3.9%)). None had a serious TEAE. Two participants (3.9%) in the placebo with therapy group discontinued treatment due to TEAEs. Frequently reported TEAEs (occurring with incidence &gt;10% and at least twice the prevalence in the MDMA-AT group versus the placebo with therapy group) included muscle tightness, nausea, decreased appetite and hyperhidrosis (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Tab2">2</a>). These were mostly transient and of mild or moderate severity. At least one treatment-emergent adverse event of special interest (TEAESI) occurred in six of 53 (11.3%) participants in the MDMA-AT group and three of 51 (5.9%) participants in the placebo with therapy group (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Tab2">2</a>). No TEAESIs of MDMA abuse, misuse, physical dependence or diversion were reported.</p><div data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption><b id="Tab2" data-test="table-caption">Table 2 Adverse events occurring during treatment</b></figcaption></figure></div><p>Eight participants (MDMA-AT, <i>n</i> = 7; placebo with therapy, <i>n</i> = 1) experienced cardiac TEAEs, which included palpitations (MDMA-AT, <i>n</i> = 5 (9.4%); placebo with therapy, <i>n</i> = 1 (2.0%)) and tachycardia (MDMA-AT, <i>n</i> = 2 (3.8%)); all were mild. Nine participants (MDMA-AT, <i>n</i> = 7; placebo with therapy, <i>n</i> = 2) experienced vascular TEAEs; all were mild, except for one participant in the MDMA-AT group who had a history of hypertension, who was not taking anti-hypertensive medications and who experienced a TEAE of moderate hypertension (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">7</a>). Five participants had cardiac TEAESIs: four participants in the MDMA-AT group and one participant in the placebo with therapy group reported palpitations (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">7</a>). Participants in the MDMA-AT group experienced temporary dose-dependent increases in mean blood pressure (BP) and pulse during experimental sessions compared to the placebo with therapy group (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">8</a>).</p><p>Transient increases in heart rate and BP were expected and were observed during experimental sessions in a dose-dependent manner. Greater fluctuations in BP were seen during experimental sessions 2 and 3 in the participants treated with MDMA, most likely due to the higher doses of MDMA administered. These transient elevations did not require clinical intervention, including among the subset of participants with well-controlled hypertension. Because the current dosing regimen involves administering a single, split drug dose under observation, for a limited number of times, each after a lengthy washout, cardiovascular risk is likely to have been sufficiently mitigated by the study procedures and screening measures.</p><p>Psychiatric TEAEs occurred at a similarly high frequency in both groups (MDMA-AT, <i>n</i> = 44 (83.0%); placebo with therapy, <i>n</i> = 37 (72.5%)), with suicidal ideation, insomnia and anxiety reported most frequently. Psychiatric TEAEs were mostly mild to moderate; three severe events occurred in the MDMA-AT group (5.7%; <i>n</i> = 1 each: dissociation, flashback and grief reaction) and two in the placebo with therapy group (3.9%; <i>n</i> = 1 each: agitation and anxiety). No severe TEAEs of suicidal ideation or behavior were reported. Two participants in the MDMA-AT group had suicidality TEAESIs of suicidal ideation, one of whom engaged in non-suicidal self-injurious behavior. Two participants in the placebo with therapy group had suicidality TEAESIs; one engaged in non-suicidal self-injurious behavior, and one had suicidal ideation and trichotillomania (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">9</a>).</p><p>More than 80% (87/104) of participants had a lifetime history of suicidal ideation; 13 of 53 (24.5%) in the MDMA-AT group and 12 of 51 (23.5%) in the placebo with therapy group reported suicidal ideation during the final preparation session (V4). The number of participants reporting positive suicidal ideation varied throughout the study but collectively never exceeded baseline values in either group (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">2</a>). Three participants (two MDMA-AT and one placebo with therapy) had treatment-emergent active suicidal ideation with at least some intent to act (Columbia-Suicide Severity Rating Scale (C-SSRS) score of 4 or 5), which was observed on five occasions (MDMA-AT, three events; placebo with therapy, two events) (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">2</a>). Of these, one participant in the MDMA-AT group with no suicidal ideation at baseline had the emergence of active suicidal ideation with at least some intent to act.</p></div></div></section><section data-title="Discussion"><div id="Sec8-section"><h2 id="Sec8">Discussion</h2><div id="Sec8-content"><p>In this confirmatory phase 3 study of participants with moderate to severe PTSD, MDMA-AT significantly improved PTSD symptoms and functional impairment, as assessed by CAPS-5 and SDS, respectively, compared to placebo with therapy over 18 weeks. Notably, 45 of 52 (86.5%) participants treated with MDMA-AT achieved a clinically meaningful benefit, and 37 of 52 (71.2%) participants no longer met criteria for PTSD by study end. In a historic first, to our knowledge, for psychedelic treatment studies, participants who identified as ethnically or racially diverse encompassed approximately half of the study sample. These findings confirm and extend the results observed in MAPP1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2698">12</a></sup>), with general consistency across endpoints.</p><p>Given the diverse population and degree of participant complexity, the replication of efficacy is particularly notable. In our study, 26.9% (28/104) of participants expressed moderate PTSD, whereas, in MAPP1, all participants expressed severe PTSD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2705">12</a></sup>. A substantial proportion of participants displayed comorbid features associated with high treatment resistance<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Roberts, N. P., Lotzin, A. &amp; Schäfer, I. A systematic review and meta-analysis of psychological interventions for comorbid post-traumatic stress disorder and substance use disorder. Eur. J. Psychotraumatol. 13, 2041831 (2022)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR5" id="ref-link-section-d290364475e2709">5</a></sup>, such as major depression, multiple sources of trauma (including childhood and combat trauma) and dissociative subtype PTSD. In keeping with MAPP1, treatment was not significantly affected by disease severity, risk of hazardous alcohol or substance use disorder, severe adverse childhood experiences or dissociative subtype. Furthermore, there was no observed site-to-site variability and no differential effect if participants stayed overnight after the experimental session. However, lifetime history of SSRIs, female sex assigned at birth and BDI-II score ≥23 at baseline were associated with positive impacts on outcomes and may warrant further study based on the exploratory nature of these analyses.</p><p>MDMA simultaneously induces prosocial feelings and softens responses to emotionally challenging and fearful stimuli<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Kamilar-Britt, P. &amp; Bedi, G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci. Biobehav. Rev. 57, 433–446 (2015)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR19" id="ref-link-section-d290364475e2716">19</a></sup>, potentially enhancing the ability of individuals with PTSD to benefit from psychotherapy by reducing sensations of fear, threat and negative emotionality<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Feduccia, A. A. &amp; Mithoefer, M. C. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog. Neuropsychopharmacol. Biol. Psychiatry 84, 221–228 (2018)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR18" id="ref-link-section-d290364475e2720">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Kamilar-Britt, P. &amp; Bedi, G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci. Biobehav. Rev. 57, 433–446 (2015)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR19" id="ref-link-section-d290364475e2723">19</a></sup>. The low dropout rate for MDMA-AT has been replicated across seven studies, suggesting that MDMA induces a true shift in participant engagement<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2727">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacol. (Berl.) 236, 2735–2745 (2019)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR13" id="ref-link-section-d290364475e2730">13</a></sup>. In contrast, a recent study comparing psychotherapies in veterans with PTSD reported dropout rates of 55.8% and 46.6% for prolonged exposure and cognitive processing therapy, respectively<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Schnurr, P. P. et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: a randomized clinical trial. JAMA Netw. Open 5, e2136921 (2022)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR31" id="ref-link-section-d290364475e2734">31</a></sup>. The MAPP2 dropout rate was 1.9% (1/53) in the MDMA-AT group and 15.7% (8/51) in the placebo with therapy group. The higher proportion of dropouts in the placebo with therapy group relative to MDMA-AT could be attributed to participants receiving less effective treatment and to disappointment from ineffective therapeutic blinding, although blinding survey data showed that not all participants correctly identified the treatment that they received.</p><p>Consistent with MAPP1, no new major safety issues were reported. Common TEAEs were similar to previous studies and consistent with expected effects of MDMA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2741">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Jerome, L. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacol. (Berl.) 237, 2485–2497 (2020)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR32" id="ref-link-section-d290364475e2744">32</a></sup>. Rates of cardiac TEAEs were low, and increases in BP and pulse were mild, transient and consistent with MDMA’s sympathomimetic effects<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Feduccia, A. A. &amp; Mithoefer, M. C. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog. Neuropsychopharmacol. Biol. Psychiatry 84, 221–228 (2018)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR18" id="ref-link-section-d290364475e2748">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Lester, S. J. et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine: a double-blind, placebo-controlled trial. Ann. Intern. Med. 133, 969–973 (2000)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR33" id="ref-link-section-d290364475e2751">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Vizeli, P. &amp; Liechti, M. E. Safety pharmacology of acute MDMA administration in healthy subjects. J. Psychopharmacol. 31, 576–588 (2017)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR34" id="ref-link-section-d290364475e2754">34</a></sup>. Consistent with PTSD, suicidal ideation was observed in both groups. MDMA did not appear to increase this risk, and no suicidal behavior was observed. C-SSRS scores varied throughout the study but never exceeded baseline values for either group. Notably, there were five total events of treatment-emergent C-SSRS scores of 4 or 5: three in the MDMA-AT group and two in the placebo with therapy group. MAPP2 enrolled participants with a history of suicidality but excluded those with a current, serious imminent suicide risk; thus, special attention to this vulnerable population is warranted in future studies. In alignment with MAPP1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2758">12</a></sup>), there were no reports of problematic MDMA abuse or dependence, including in participants with histories of, or current, alcohol and substance use disorders. However, it is important to note that participants with any substance use disorder other than cannabis or alcohol in the 12 months before enrollment were excluded from MAPP2, as were participants with severe or moderate (in early remission) alcohol or cannabis use disorder. However, exploratory findings from the MAPP1 phase 3 trial indicated that MDMA-AT was actually associated with a significantly greater reduction in mean Alcohol Use Disorder Identification Test change scores compared to placebo with therapy, suggesting that the effects of MDMA-AT on hazardous alcohol use secondary to PTSD should be further studied<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Nicholas, C. R. et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 233, 109356 (2022)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR35" id="ref-link-section-d290364475e2762">35</a></sup>. Long-term data are also needed to assess the risk of MDMA abuse or misuse after study participation.</p><p>Although the sample sizes of the MAPP1 and MAPP2 phase 3 studies had 90% statistical power and were developed with guidance from the FDA to ensure adequate, rigorous testing of outcomes, these evaluations did not extend further than 2 months after therapy and were intended to support an acute treatment course. To support these studies, data from the ongoing follow-up of participants from phase 2 and 3 studies (ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT05066282">NCT05066282</a>) will be important for further assessment of the long-term effectiveness of MDMA-AT in participants with PTSD. It is of interest to note that pooled phase 2 analyses of participants with at least 12 months of follow-up after their final MDMA-AT session have shown that LS mean CAPS-IV scores continue to improve between the final session and follow-up<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Jerome, L. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacol. (Berl.) 237, 2485–2497 (2020)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR32" id="ref-link-section-d290364475e2777">32</a></sup>.</p><p>Several limitations may impact the integration of MDMA-AT into clinical care, including the exclusion of participants with high suicide risk, comorbid personality disorders and underlying cardiovascular disease. Observed effect sizes for MDMA-AT (between-group, <i>d</i> = 0.7; within-subject, <i>d</i> = 1.95) were similar to MAPP1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2790">12</a></sup>) (between-group, <i>d</i> = 0.91; within-subject, <i>d</i> = 2.1), and, although higher than those observed in SSRI studies (ranging from 0.09 to 0.56 versus placebo for sertraline and paroxetine<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Feduccia, A. A. et al. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front. Psychiatry 10, 650 (2019)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR36" id="ref-link-section-d290364475e2801">36</a></sup>), the superiority of MDMA-AT over SSRIs cannot be assumed without a direct comparison. The complex relationship between SSRI use/history and MDMA-AT treatment efficacy was beyond the scope of the current statistical analysis plan and sample size but will be important to consider in future studies. In addition, further study of MDMA with other forms of psychotherapy for PTSD should be explored.</p><p>The notable effect seen in the placebo with therapy arm could suggest the standalone value of the manualized inner-directed therapy that was developed for use with MDMA. Additional head-to-head studies will need to be conducted to evaluate whether this form of manualized therapy provides greater value in the treatment of PTSD than the current first-line cognitive behavioral therapy and prolonged exposure therapy treatments<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="US Department of Veteran Affairs. PTSD: National Center for PTSD. Clinician’s guide to medications for PTSD (
                https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp
                
              )." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR37" id="ref-link-section-d290364475e2808">37</a></sup>.</p><p>Although treatment expectancy, per se, was not measured in this study, prospective treatment expectancy would likely have been high in both study arms, with random assignment expected to distribute this equally between groups. Although expectancy effects are a well-known issue in psychiatric clinical trials and are intertwined with the observation of treatment benefit during a trial<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Schenberg, E. E. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev. Clin. Pharm. 14, 1317–1319 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR38" id="ref-link-section-d290364475e2815">38</a></sup>, several observations support expectancy mitigation in the current study: (1) the groups did not separate after the first experimental session; (2) placebo with therapy dropouts did not uniformly occur after the first experimental session; and (3) blinding survey data (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">6</a>) showed that not all participants correctly identified the treatment that they received.</p><p>The therapists who participated in this study were required to complete the sponsor’s training program (see <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a> for further details). To ensure consistent clinical practice and to mitigate harm, it may be of benefit for prescribers to complete additional training and continuing education if MDMA-AT is approved for use by a regulatory agency.</p><p>This confirmatory phase 3 trial showed consistent benefits of MDMA-AT in an ethnoracially diverse group of individuals with longstanding moderate to severe PTSD and numerous comorbidities. The dropout rate was low, and treatment was generally well tolerated. These findings represent the culmination of over two decades of research<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Doblin, R. A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J. Psychoact. Drugs 34, 185–194 (2002)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR39" id="ref-link-section-d290364475e2831">39</a></sup>, and, together with MAPP1, indicate that further consideration of this treatment in individuals with moderate to severe PTSD is warranted.</p></div></div></section><section data-title="Methods"><div id="Sec9-section"><h2 id="Sec9">Methods</h2><div id="Sec9-content"><h3 id="Sec10">Study design and oversight</h3><p>This multi-site, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of MDMA-AT versus placebo with therapy in participants diagnosed with moderate or severe PTSD (<a href="https://clinicaltrials.gov/ct2/show/NCT04077437">NCT04077437</a>). Thirteen study sites (11 in the United States and two in Israel, both institutional and private) participated. The trial was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonization and with the ethical principles of the Declaration of Helsinki. An independent data monitoring committee ensured that the study was conducted safely and had sufficient sample size. The review boards and institutions that approved the study protocol are listed in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a>.</p><h3 id="Sec11">Participants</h3><p>After written informed consent, participants were screened for eligibility. Adults (≥18 years of age) meeting the full DSM-5 criteria for current PTSD per CAPS-5 assessment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Weathers, F. W. et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) 
                https://www.ptsd.va.gov/
                
               (2013)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR40" id="ref-link-section-d290364475e2865">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Weathers, F. W. et al. The clinician administered PTSD scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol. Assess. 30, 383–395 (2018)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR41" id="ref-link-section-d290364475e2868">41</a></sup> and a CAPS-5 total severity score ≥28 (moderate or higher severity) with symptom duration of ≥6 months were eligible for enrollment confirmation. During the Preparation Period that preceded the Treatment Period, participants were tapered off all psychiatric medications before baseline to avoid potential drug interactions and confounding efficacy (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">1</a>). Full inclusion and exclusion criteria are outlined in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a>.</p><h3 id="Sec12">Randomization and masking</h3><p>Participants were randomized in a 1:1 allocation and in a blinded fashion to the MDMA-AT and placebo with therapy groups, stratified by clinical site. Randomization was managed via an interactive web randomization system (IWRS) (IT Clinical version 11.0.1) based on a centralized randomization schedule developed by an independent third-party vendor to maintain blinding.</p><p>A central pool of blinded independent assessors was used to mitigate the risk of functional unblinding<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Targum, S. D., Daly, E., Fedgchin, M., Cooper, K. &amp; Singh, J. B. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. J. Psychiatr. Res 111, 68–73 (2019)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR42" id="ref-link-section-d290364475e2889">42</a></sup>. Assessors were trained and supervised by independent consultants with expertise in PTSD diagnostics and the CAPS-5 to ensure inter-rater reliability and validity of assessments. Supervision involved reviewing each assessor’s first two assessments as well as 20% of all assessments (chosen at random) throughout the study, with each review resulting in detailed feedback for the assessor. The independent assessors were blinded to the general study design, study visit, treatment assignment, number of treatments received and any safety data for the participant. Participants were instructed to withhold their opinion on treatment group assignment and the number of completed visits from the independent assessors. Each assessor conducted no more than one CAPS-5 assessment with each participant to reduce potential bias and expectancy effect from having conducted repeat CAPS-5s with a participant. Assessors were also vetted before their onboarding to ensure that there were no conflicts of interest (such as other involvement within the Multidisciplinary Association for Psychedelic Studies (MAPS) organization or a bias toward MDMA-AT), and assessors were instructed to not expose themselves to scholarly presentations and papers related to MDMA-AT for PTSD to maintain their blinding to study design.</p><p>To ensure that all site and sponsor staff were shielded from study outcomes, the blinded independent assessor pool collected and stored outcome measures in a dedicated database that was separate from the blinded clinical database. A blinding survey was conducted at study termination (visit 20) to assess if participants thought that they received MDMA or placebo.</p><h3 id="Sec13">Procedures</h3><p>Trial procedures were consistent with MAPP1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2904">12</a></sup>). Enrolled participants underwent three 90-min preparation sessions with a two-person therapy team, including at least one licensed therapist, and were then randomized 1:1 to receive MDMA-AT or placebo with therapy for approximately 3 months. The treatment period consisted of three 8-h dosing sessions, in conjunction with therapy, spaced approximately 1 month apart. Therapy was conducted by trained personnel in accordance with the MAPS MDMA-AT treatment manual (<a href="https://maps.org/treatment-manual">https://maps.org/treatment-manual</a>) and trial protocol. During experimental sessions, and in keeping with the dosing in MAPP1, participants received a split dose of 120–180 mg of MDMA or placebo. For the first experimental session, the initial dose of 80 mg was followed by a supplemental half-dose of 40 mg. In the second and third experimental sessions, the initial dose of 120 mg was followed by a supplemental half-dose of 60 mg. The supplemental half dose was administered 1.5–2 h after the initial dose. Participants in both treatment groups received identical therapy. The 120-mg (80 mg + 40 mg) split dose was selected for the first experimental session in phase 3 trials to allow patients to acclimate to the treatment regimen using a clinical titration approach based on clinician recommendations from a phase 2 trial in veterans and first responders<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacol. (Berl.) 236, 2735–2745 (2019)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR13" id="ref-link-section-d290364475e2915">13</a></sup>. During the second and third experimental sessions, doses were escalated to 180 mg (120 mg + 60 mg), as this was the most frequently studied efficacious dose in phase 2 trials. This dosing regimen also provides clinicians with the option of dose adjustments if needed.</p><p>Within the MDMA-AT group, three participants did not undergo dose escalation in experimental sessions 2 and 3, and two participants experienced dose administration timing errors (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">2</a>). Each experimental session was followed by three 90-min integration sessions to support participants in processing and understanding their experience (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">1</a>). Full procedures, including details on therapy teams and training, are outlined in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a>.</p><h3 id="Sec14">Outcomes</h3><p>Independent assessors conducted CAPS-5 and SDS outcome assessments at baseline, after experimental sessions 1 and 2 and 6–8 weeks after experimental session 3 (18 weeks after baseline) via video interviews. Primary and secondary objectives were mean change in CAPS-5 total severity and SDS scores, respectively, for MDMA-AT versus placebo with therapy from baseline to 18 weeks after baseline.</p><p>Exploratory outcome measurements included characterization of the treatment response and differences between the treatment groups by demographics and characteristics. Responder analyses were based on categorical diagnostic assessment data and the CAPS-5 total severity score assessment. PTSD severity was defined using the CAPS-5 total severity score as follows: asymptomatic (0–10), mild (11–22), moderate (23–34), severe (35–46) and extreme (47+) (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Weathers, F. W. et al. The clinician administered PTSD scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol. Assess. 30, 383–395 (2018)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR41" id="ref-link-section-d290364475e2943">41</a></sup>). A ≥10-point reduction in CAPS-5 total severity score was considered to be clinically meaningful as agreed upon with the FDA through a Special Protocol Assessment. Four responder categories were derived and compared at each post-experimental session visit using CAPS-5 scores. These categories were: non-responder (&lt;10-point reduction from baseline), responder (≥10-point reduction from baseline), loss of diagnosis (≥10-point reduction from baseline and no longer meeting PTSD diagnostic criteria) and remission (CAPS-5 total severity score of 11 or less and no longer meeting PTSD diagnostic criteria).</p><p>Safety objectives included assessment of differences between groups in severity, incidence and frequency of TEAEs, serious TEAEs, TEAESIs, suicidal ideation and behavior and vital signs. TEAEs were defined as any adverse event that occurred during the treatment period from the first experimental session to the last integration session. The severity of TEAEs was determined by the site physician as mild (no limitation in normal daily activity), moderate (some limitation in normal daily activity) or severe (unable to perform normal daily activity). A serious TEAE was defined as any unforeseen medical event at any dose of the drug that resulted in death; was life-threatening; required inpatient hospitalization; caused significant disability or incapacity; resulted in a congenital anomaly or birth defect; or required intervention to prevent permanent impairment or damage. Serious TEAEs also included any event, based on medical judgement, that jeopardized the participant or may have required intervention to prevent one of the events listed previously. With the exception of serious adverse event reporting, relatedness to study drug was not assessed by investigators, to preserve blinding. In an effort to identify common adverse events that may be most related to MDMA, TEAEs occurring with incidence &gt;10% and at least twice the prevalence in the MDMA-AT group versus the placebo with therapy group are reported. Suicidality was tracked at each study visit using the C-SSRS (see the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a> for more information).</p><h3 id="Sec15">Statistical analysis</h3><p>SAS version 9.4 (SAS Institute) was used for analyses. Sample size was calculated to achieve a power of 90% at an alpha of 0.0499.</p><p>Efficacy was tested using an MMRM analysis comparing the change from baseline to 18 weeks after baseline in CAPS-5 and SDS scores between treatment groups in two-sided tests with alpha set at 0.0499. The alpha was adjusted to account for an administrative interim analysis for sample size re-estimation conducted after all participants were enrolled and 60% of primary endpoint data had been collected. Fixed effects were treatment, visit, treatment group by visit interaction and dissociative subtype; baseline CAPS-5 score was a covariate. Primary and secondary efficacy analyses used a de jure (related to initially randomized treatment) estimand and a supportive de facto (treatment policy) estimand of the modified intention-to-treat population, which required exposure to MDMA or placebo and at least one follow-up CAPS-5 assessment, as in MAPP1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021)." href="https://jvns.ca/articles/s41591-023-02565-4#ref-CR12" id="ref-link-section-d290364475e2964">12</a></sup>). The de jure dataset included all available data, except for 12 (one MDMA-AT and 11 placebo with therapy) outcome measurements taken after treatment discontinuation in analysis of treatment efficacy (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">3</a>). Missed observations were considered missing at random (MAR), and choice of this assumption was tested with a tipping point analysis (<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a>).</p><p>In additional exploratory analyses, 13 covariates were assessed in the model, with alpha set at 0.0499: age, sex (self-reported), prior use of selective SSRIs, work disability, disease severity, PTSD duration, dissociative subtype, overnight site stay, site ID, moderate depression (as measured by the BDI-II), severe adverse childhood experiences and moderate alcohol and substance use disorder risk (as measured by the Drug Use Disorders Identification Test and the Alcohol Use Disorders Identification Test). Analyses of primary or secondary outcomes by gender were not planned a priori; some exploratory analyses included sex as a covariate (<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Methods</a>).</p><p>Safety analysis evaluated TEAEs at the participant level, including all participants who received MDMA or placebo. Causal association with MDMA was determined based on relative incidence of TEAEs with at least a two-fold difference between groups.</p><h3 id="Sec16">Adverse events of special interest</h3><p>In accordance with FDA guidance, special attention was paid to a subset of adverse events, TEAESIs, relating to cardiac function, suicide risk and MDMA abuse, misuse or diversion. TEAESIs involving cardiac function that could be indicative of QT prolongation or cardiac arrhythmias were collected, including torsade de pointes, sudden death, ventricular extrasystoles, ventricular tachycardia, ventricular fibrillation and flutter, non-postural syncope and seizures. TEAESIs involving suicide risk included suicide, suicide attempts, self-harm associated with suicidal ideation, suicide ideation assessed as a score of 4 or 5 on the C-SSRS and suicidal ideation judged by the investigator to be serious/severe. TEAESIs involving terms of MDMA abuse, misuse, drug diversion, dependence or overdose were also collected.</p><h3 id="Sec17">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM2">Nature Portfolio Reporting Summary</a> linked to this article.</p></div></div></section>
                </div><div>
            <section data-title="Data availability"><div id="data-availability-section"><h2 id="data-availability">Data availability</h2><p>The data that support the findings of this study are available from the sponsor beginning 1 year after completion of the trial. However, restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are, however, available from the authors upon reasonable request and with the permission of the sponsor. All requests for raw and analyzed data are promptly reviewed to verify if the request is subject to any confidentiality obligations. Participant-related data not included in the paper were generated as part of clinical trials and may be subject to participant confidentiality. Any data that can be shared will be released via a data use agreement. Proposals should be directed to <a href="https://maps.org/datause">https:/maps.org/datause</a>. <a data-track="click" data-track-label="link" data-track-action="section anchor" href="https://jvns.ca/articles/s41591-023-02565-4#Sec20">Source data</a> are provided with this paper.</p></div></section><section data-title="Code availability"><div id="code-availability-section"><h2 id="code-availability">Code availability</h2><p>Commercially available software (SAS version 9.4 or higher, SAS Institute) was used for analyses, in keeping with the statistical analysis plan.</p></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div id="Bib1-section"><h2 id="Bib1">References</h2><div id="Bib1-content"><div data-container-section="references"><ol data-track-component="outbound reference"><li data-counter="1."><p id="ref-CR1">US Department of Veteran Affairs. PTSD: National Center for PTSD. How common is PTSD in adults? (<a href="https://www.ptsd.va.gov/understand/common/common_adults.asp" data-track="click" data-track-action="external reference" data-track-label="https://www.ptsd.va.gov/understand/common/common_adults.asp">https://www.ptsd.va.gov/understand/common/common_adults.asp</a>).</p></li><li data-counter="2."><p id="ref-CR2">de Silva, U., Glover, N. &amp; Katona, C. Prevalence of complex post-traumatic stress disorder in refugees and asylum seekers: systematic review. <i>BJPysch Open</i> <b>7</b>, e194 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1192/bjo.2021.1013" data-track-action="article reference" href="https://doi.org/10.1192%2Fbjo.2021.1013" aria-label="Article reference 2" data-doi="10.1192/bjo.2021.1013">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20of%20complex%20post-traumatic%20stress%20disorder%20in%20refugees%20and%20asylum%20seekers%3A%20systematic%20review&amp;journal=BJPysch%20Open&amp;doi=10.1192%2Fbjo.2021.1013&amp;volume=7&amp;publication_year=2021&amp;author=Silva%2CU&amp;author=Glover%2CN&amp;author=Katona%2CC">
                    Google Scholar</a> 
                </p></li><li data-counter="3."><p id="ref-CR3">de Castro Longo, M. S. et al. Comorbidity in post-traumatic stress disorder: a population-based study from the two largest cities in Brazil. <i>J. Affect. Disord.</i> <b>263</b>, 715–721 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.jad.2019.11.051" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jad.2019.11.051" aria-label="Article reference 3" data-doi="10.1016/j.jad.2019.11.051">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Comorbidity%20in%20post-traumatic%20stress%20disorder%3A%20a%20population-based%20study%20from%20the%20two%20largest%20cities%20in%20Brazil&amp;journal=J.%20Affect.%20Disord.&amp;doi=10.1016%2Fj.jad.2019.11.051&amp;volume=263&amp;pages=715-721&amp;publication_year=2020&amp;author=Castro%20Longo%2CMS">
                    Google Scholar</a> 
                </p></li><li data-counter="4."><p id="ref-CR4">Hill, S. B. et al. Dissociative subtype of posttraumatic stress disorder in women in partial and residential levels of psychiatric care. <i>J. Trauma Dissociation</i> <b>21</b>, 305–318 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/15299732.2019.1678214" data-track-action="article reference" href="https://doi.org/10.1080%2F15299732.2019.1678214" aria-label="Article reference 4" data-doi="10.1080/15299732.2019.1678214">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31607239" aria-label="PubMed reference 4">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Dissociative%20subtype%20of%20posttraumatic%20stress%20disorder%20in%20women%20in%20partial%20and%20residential%20levels%20of%20psychiatric%20care&amp;journal=J.%20Trauma%20Dissociation&amp;doi=10.1080%2F15299732.2019.1678214&amp;volume=21&amp;pages=305-318&amp;publication_year=2020&amp;author=Hill%2CSB">
                    Google Scholar</a> 
                </p></li><li data-counter="5."><p id="ref-CR5">Roberts, N. P., Lotzin, A. &amp; Schäfer, I. A systematic review and meta-analysis of psychological interventions for comorbid post-traumatic stress disorder and substance use disorder. <i>Eur. J. Psychotraumatol.</i> <b>13</b>, 2041831 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/20008198.2022.2041831" data-track-action="article reference" href="https://doi.org/10.1080%2F20008198.2022.2041831" aria-label="Article reference 5" data-doi="10.1080/20008198.2022.2041831">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35558682" aria-label="PubMed reference 5">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090345" aria-label="PubMed Central reference 5">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20systematic%20review%20and%20meta-analysis%20of%20psychological%20interventions%20for%20comorbid%20post-traumatic%20stress%20disorder%20and%20substance%20use%20disorder&amp;journal=Eur.%20J.%20Psychotraumatol.&amp;doi=10.1080%2F20008198.2022.2041831&amp;volume=13&amp;publication_year=2022&amp;author=Roberts%2CNP&amp;author=Lotzin%2CA&amp;author=Sch%C3%A4fer%2CI">
                    Google Scholar</a> 
                </p></li><li data-counter="6."><p id="ref-CR6">Lewis, C., Roberts, N. P., Gibson, S. &amp; Bisson, J. I. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. <i>Eur. J. Psychotraumatol.</i> <b>11</b>, 1709709 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/20008198.2019.1709709" data-track-action="article reference" href="https://doi.org/10.1080%2F20008198.2019.1709709" aria-label="Article reference 6" data-doi="10.1080/20008198.2019.1709709">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32284816" aria-label="PubMed reference 6">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144189" aria-label="PubMed Central reference 6">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Dropout%20from%20psychological%20therapies%20for%20post-traumatic%20stress%20disorder%20%28PTSD%29%20in%20adults%3A%20systematic%20review%20and%20meta-analysis&amp;journal=Eur.%20J.%20Psychotraumatol.&amp;doi=10.1080%2F20008198.2019.1709709&amp;volume=11&amp;publication_year=2020&amp;author=Lewis%2CC&amp;author=Roberts%2CNP&amp;author=Gibson%2CS&amp;author=Bisson%2CJI">
                    Google Scholar</a> 
                </p></li><li data-counter="7."><p id="ref-CR7">Steenkamp, M. M., Litz, B. T., Hoge, C. W. &amp; Marmar, C. R. Psychotherapy for military-related PTSD: a review of randomized clinical trials. <i>JAMA</i> <b>314</b>, 489–500 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jama.2015.8370" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2015.8370" aria-label="Article reference 7" data-doi="10.1001/jama.2015.8370">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtlOlu7bP" aria-label="CAS reference 7">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26241600" aria-label="PubMed reference 7">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychotherapy%20for%20military-related%20PTSD%3A%20a%20review%20of%20randomized%20clinical%20trials&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2015.8370&amp;volume=314&amp;pages=489-500&amp;publication_year=2015&amp;author=Steenkamp%2CMM&amp;author=Litz%2CBT&amp;author=Hoge%2CCW&amp;author=Marmar%2CCR">
                    Google Scholar</a> 
                </p></li><li data-counter="8."><p id="ref-CR8">Mavranezouli, I. et al. Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. <i>Psychol. Med.</i> <b>50</b>, 542–555 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1017/S0033291720000070" data-track-action="article reference" href="https://doi.org/10.1017%2FS0033291720000070" aria-label="Article reference 8" data-doi="10.1017/S0033291720000070">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32063234" aria-label="PubMed reference 8">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychological%20treatments%20for%20post-traumatic%20stress%20disorder%20in%20adults%3A%20a%20network%20meta-analysis&amp;journal=Psychol.%20Med.&amp;doi=10.1017%2FS0033291720000070&amp;volume=50&amp;pages=542-555&amp;publication_year=2020&amp;author=Mavranezouli%2CI">
                    Google Scholar</a> 
                </p></li><li data-counter="9."><p id="ref-CR9">Alexander, W. Pharmacotherapy for post-traumatic stress disorder in combat veterans: focus on antidepressants and atypical antipsychotic agents. <i>Pharm. Ther.</i> <b>37</b>, 32 (2012).</p><p><a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Pharmacotherapy%20for%20post-traumatic%20stress%20disorder%20in%20combat%20veterans%3A%20focus%20on%20antidepressants%20and%20atypical%20antipsychotic%20agents&amp;journal=Pharm.%20Ther.&amp;volume=37&amp;publication_year=2012&amp;author=Alexander%2CW">
                    Google Scholar</a> 
                </p></li><li data-counter="10."><p id="ref-CR10">Davis, L. L. et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective. <i>J. Clin. Psychiatry</i> <b>83</b>, 21m14116 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.4088/JCP.21m14116" data-track-action="article reference" href="https://doi.org/10.4088%2FJCP.21m14116" aria-label="Article reference 10" data-doi="10.4088/JCP.21m14116">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35485933" aria-label="PubMed reference 10">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20economic%20burden%20of%20posttraumatic%20stress%20disorder%20in%20the%20United%20States%20from%20a%20societal%20perspective&amp;journal=J.%20Clin.%20Psychiatry&amp;doi=10.4088%2FJCP.21m14116&amp;volume=83&amp;publication_year=2022&amp;author=Davis%2CLL">
                    Google Scholar</a> 
                </p></li><li data-counter="11."><p id="ref-CR11">Couette, M., Mouchabac, S., Bourla, A., Nuss, P. &amp; Ferreri, F. Social cognition in post-traumatic stress disorder: a systematic review. <i>Br. J. Clin. Psychol.</i> <b>59</b>, 117–138 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1111/bjc.12238" data-track-action="article reference" href="https://doi.org/10.1111%2Fbjc.12238" aria-label="Article reference 11" data-doi="10.1111/bjc.12238">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31696974" aria-label="PubMed reference 11">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Social%20cognition%20in%20post-traumatic%20stress%20disorder%3A%20a%20systematic%20review&amp;journal=Br.%20J.%20Clin.%20Psychol.&amp;doi=10.1111%2Fbjc.12238&amp;volume=59&amp;pages=117-138&amp;publication_year=2020&amp;author=Couette%2CM&amp;author=Mouchabac%2CS&amp;author=Bourla%2CA&amp;author=Nuss%2CP&amp;author=Ferreri%2CF">
                    Google Scholar</a> 
                </p></li><li data-counter="12."><p id="ref-CR12">Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. <i>Nat. Med.</i> <b>27</b>, 1025–1033 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41591-021-01336-3" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-021-01336-3" aria-label="Article reference 12" data-doi="10.1038/s41591-021-01336-3">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtVKlsbvL" aria-label="CAS reference 12">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33972795" aria-label="PubMed reference 12">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205851" aria-label="PubMed Central reference 12">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=MDMA-assisted%20therapy%20for%20severe%20PTSD%3A%20a%20randomized%2C%20double-blind%2C%20placebo-controlled%20phase%203%20study&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01336-3&amp;volume=27&amp;pages=1025-1033&amp;publication_year=2021&amp;author=Mitchell%2CJM">
                    Google Scholar</a> 
                </p></li><li data-counter="13."><p id="ref-CR13">Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. <i>Psychopharmacol. (Berl.)</i> <b>236</b>, 2735–2745 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00213-019-05249-5" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00213-019-05249-5" aria-label="Article reference 13" data-doi="10.1007/s00213-019-05249-5">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BC1MXptVSrurw%3D" aria-label="CAS reference 13">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=MDMA-assisted%20psychotherapy%20for%20treatment%20of%20PTSD%3A%20study%20design%20and%20rationale%20for%20phase%203%20trials%20based%20on%20pooled%20analysis%20of%20six%20phase%202%20randomized%20controlled%20trials&amp;journal=Psychopharmacol.%20%28Berl.%29&amp;doi=10.1007%2Fs00213-019-05249-5&amp;volume=236&amp;pages=2735-2745&amp;publication_year=2019&amp;author=Mithoefer%2CMC">
                    Google Scholar</a> 
                </p></li><li data-counter="14."><p id="ref-CR14">Nichols, D. E. Entactogens: how the name for a novel class of psychoactive agents originated. <i>Front. Psychiatry</i> <b>13</b>, 863088 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fpsyt.2022.863088" data-track-action="article reference" href="https://doi.org/10.3389%2Ffpsyt.2022.863088" aria-label="Article reference 14" data-doi="10.3389/fpsyt.2022.863088">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35401275" aria-label="PubMed reference 14">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990025" aria-label="PubMed Central reference 14">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Entactogens%3A%20how%20the%20name%20for%20a%20novel%20class%20of%20psychoactive%20agents%20originated&amp;journal=Front.%20Psychiatry&amp;doi=10.3389%2Ffpsyt.2022.863088&amp;volume=13&amp;publication_year=2022&amp;author=Nichols%2CDE">
                    Google Scholar</a> 
                </p></li><li data-counter="15."><p id="ref-CR15">Mayer, F. P. et al. Serotonin-releasing agents with reduced off-target effects. <i>Mol. Psychiatry</i> <b>28</b>, 722–732 (2023).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1038/s41380-022-01843-w" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41380-022-01843-w" aria-label="Article reference 15" data-doi="10.1038/s41380-022-01843-w">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB38XivVCks77L" aria-label="CAS reference 15">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36352123" aria-label="PubMed reference 15">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Serotonin-releasing%20agents%20with%20reduced%20off-target%20effects&amp;journal=Mol.%20Psychiatry&amp;doi=10.1038%2Fs41380-022-01843-w&amp;volume=28&amp;pages=722-732&amp;publication_year=2023&amp;author=Mayer%2CFP">
                    Google Scholar</a> 
                </p></li><li data-counter="16."><p id="ref-CR16">Sandtner, W. et al. Binding mode selection determines the action of ecstasy homologs at monoamine transporters. <i>Mol. Pharmacol.</i> <b>89</b>, 165 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1124/mol.115.101394" data-track-action="article reference" href="https://doi.org/10.1124%2Fmol.115.101394" aria-label="Article reference 16" data-doi="10.1124/mol.115.101394">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BC28XisVOisb8%3D" aria-label="CAS reference 16">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26519222" aria-label="PubMed reference 16">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702095" aria-label="PubMed Central reference 16">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Binding%20mode%20selection%20determines%20the%20action%20of%20ecstasy%20homologs%20at%20monoamine%20transporters&amp;journal=Mol.%20Pharmacol.&amp;doi=10.1124%2Fmol.115.101394&amp;volume=89&amp;publication_year=2016&amp;author=Sandtner%2CW">
                    Google Scholar</a> 
                </p></li><li data-counter="17."><p id="ref-CR17">Sáez-Briones, P. &amp; Hernández, A. MDMA (3,4-methylenedioxymethamphetamine) analogues as tools to characterize MDMA-like effects: an approach to understand entactogen pharmacology. <i>Curr. Neuropharmacol.</i> <b>11</b>, 521–534 (2013).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.2174/1570159X11311050007" data-track-action="article reference" href="https://doi.org/10.2174%2F1570159X11311050007" aria-label="Article reference 17" data-doi="10.2174/1570159X11311050007">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24403876" aria-label="PubMed reference 17">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763760" aria-label="PubMed Central reference 17">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=MDMA%20%283%2C4-methylenedioxymethamphetamine%29%20analogues%20as%20tools%20to%20characterize%20MDMA-like%20effects%3A%20an%20approach%20to%20understand%20entactogen%20pharmacology&amp;journal=Curr.%20Neuropharmacol.&amp;doi=10.2174%2F1570159X11311050007&amp;volume=11&amp;pages=521-534&amp;publication_year=2013&amp;author=S%C3%A1ez-Briones%2CP&amp;author=Hern%C3%A1ndez%2CA">
                    Google Scholar</a> 
                </p></li><li data-counter="18."><p id="ref-CR18">Feduccia, A. A. &amp; Mithoefer, M. C. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? <i>Prog. Neuropsychopharmacol. Biol. Psychiatry</i> <b>84</b>, 221–228 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.pnpbp.2018.03.003" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.pnpbp.2018.03.003" aria-label="Article reference 18" data-doi="10.1016/j.pnpbp.2018.03.003">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BC1cXlsV2gtLc%3D" aria-label="CAS reference 18">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29524515" aria-label="PubMed reference 18">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=MDMA-assisted%20psychotherapy%20for%20PTSD%3A%20are%20memory%20reconsolidation%20and%20fear%20extinction%20underlying%20mechanisms%3F&amp;journal=Prog.%20Neuropsychopharmacol.%20Biol.%20Psychiatry&amp;doi=10.1016%2Fj.pnpbp.2018.03.003&amp;volume=84&amp;pages=221-228&amp;publication_year=2018&amp;author=Feduccia%2CAA&amp;author=Mithoefer%2CMC">
                    Google Scholar</a> 
                </p></li><li data-counter="19."><p id="ref-CR19">Kamilar-Britt, P. &amp; Bedi, G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. <i>Neurosci. Biobehav. Rev.</i> <b>57</b>, 433–446 (2015).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.neubiorev.2015.08.016" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.neubiorev.2015.08.016" aria-label="Article reference 19" data-doi="10.1016/j.neubiorev.2015.08.016">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFyhsbfE" aria-label="CAS reference 19">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26408071" aria-label="PubMed reference 19">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678620" aria-label="PubMed Central reference 19">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20prosocial%20effects%20of%203%2C4-methylenedioxymethamphetamine%20%28MDMA%29%3A%20controlled%20studies%20in%20humans%20and%20laboratory%20animals&amp;journal=Neurosci.%20Biobehav.%20Rev.&amp;doi=10.1016%2Fj.neubiorev.2015.08.016&amp;volume=57&amp;pages=433-446&amp;publication_year=2015&amp;author=Kamilar-Britt%2CP&amp;author=Bedi%2CG">
                    Google Scholar</a> 
                </p></li><li data-counter="20."><p id="ref-CR20">Vizeli, P. et al. Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. <i>Front. Pharm.</i> <b>13</b>, 906639 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fphar.2022.906639" data-track-action="article reference" href="https://doi.org/10.3389%2Ffphar.2022.906639" aria-label="Article reference 20" data-doi="10.3389/fphar.2022.906639">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB38XitFGns7rL" aria-label="CAS reference 20">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Effects%20of%203%2C4-methylenedioxymethamphetamine%20on%20conditioned%20fear%20extinction%20and%20retention%20in%20a%20crossover%20study%20in%20healthy%20subjects&amp;journal=Front.%20Pharm.&amp;doi=10.3389%2Ffphar.2022.906639&amp;volume=13&amp;publication_year=2022&amp;author=Vizeli%2CP">
                    Google Scholar</a> 
                </p></li><li data-counter="21."><p id="ref-CR21">Maples-Keller, J. L. et al. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. <i>J. Psychopharmacol.</i> <b>36</b>, 368–377 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/02698811211069124" data-track-action="article reference" href="https://doi.org/10.1177%2F02698811211069124" aria-label="Article reference 21" data-doi="10.1177/02698811211069124">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB38XmtVKmsL4%3D" aria-label="CAS reference 21">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35166140" aria-label="PubMed reference 21">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191244" aria-label="PubMed Central reference 21">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20randomized%20controlled%20trial%20of%203%2C4-methylenedioxymethamphetamine%20%28MDMA%29%20and%20fear%20extinction%20retention%20in%20healthy%20adults&amp;journal=J.%20Psychopharmacol.&amp;doi=10.1177%2F02698811211069124&amp;volume=36&amp;pages=368-377&amp;publication_year=2022&amp;author=Maples-Keller%2CJL">
                    Google Scholar</a> 
                </p></li><li data-counter="22."><p id="ref-CR22">Hysek, C. M. et al. MDMA enhances emotional empathy and prosocial behavior. <i>Soc. Cogn. Affect. Neurosci.</i> <b>9</b>, 1645–1652 (2014).</p></li><li data-counter="23."><p id="ref-CR23">Brooks Holliday, S. et al. The association between discrimination and PTSD in African Americans: exploring the role of gender. <i>Ethn. Health</i> <b>25</b>, 717–731 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/13557858.2018.1444150" data-track-action="article reference" href="https://doi.org/10.1080%2F13557858.2018.1444150" aria-label="Article reference 23" data-doi="10.1080/13557858.2018.1444150">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29490467" aria-label="PubMed reference 23">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20association%20between%20discrimination%20and%20PTSD%20in%20African%20Americans%3A%20exploring%20the%20role%20of%20gender&amp;journal=Ethn.%20Health&amp;doi=10.1080%2F13557858.2018.1444150&amp;volume=25&amp;pages=717-731&amp;publication_year=2020&amp;author=Brooks%20Holliday%2CS">
                    Google Scholar</a> 
                </p></li><li data-counter="24."><p id="ref-CR24">Goldstein, R. B. et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. <i>Soc. Psychiatry Psychiatr. Epidemiol.</i> <b>51</b>, 1137–1148 (2016).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00127-016-1208-5" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00127-016-1208-5" aria-label="Article reference 24" data-doi="10.1007/s00127-016-1208-5">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27106853" aria-label="PubMed reference 24">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980174" aria-label="PubMed Central reference 24">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20epidemiology%20of%20DSM-5%20posttraumatic%20stress%20disorder%20in%20the%20United%20States%3A%20results%20from%20the%20National%20Epidemiologic%20Survey%20on%20Alcohol%20and%20Related%20Conditions-III&amp;journal=Soc.%20Psychiatry%20Psychiatr.%20Epidemiol.&amp;doi=10.1007%2Fs00127-016-1208-5&amp;volume=51&amp;pages=1137-1148&amp;publication_year=2016&amp;author=Goldstein%2CRB">
                    Google Scholar</a> 
                </p></li><li data-counter="25."><p id="ref-CR25">Zimmerman, M., Benjamin, I. &amp; Seijas-Rodriguez, C. Psychiatric diagnoses among transgender and gender diverse patients compared to cisgender patients. <i>J. Clin. Psychiatry</i> <b>83</b>, 21m14062 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.4088/JCP.21m14062" data-track-action="article reference" href="https://doi.org/10.4088%2FJCP.21m14062" aria-label="Article reference 25" data-doi="10.4088/JCP.21m14062">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36170202" aria-label="PubMed reference 25">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Psychiatric%20diagnoses%20among%20transgender%20and%20gender%20diverse%20patients%20compared%20to%20cisgender%20patients&amp;journal=J.%20Clin.%20Psychiatry&amp;doi=10.4088%2FJCP.21m14062&amp;volume=83&amp;publication_year=2022&amp;author=Zimmerman%2CM&amp;author=Benjamin%2CI&amp;author=Seijas-Rodriguez%2CC">
                    Google Scholar</a> 
                </p></li><li data-counter="26."><p id="ref-CR26">Herman, J. L. Complex PTSD: a syndrome in survivors of prolonged and repeated trauma. <i>J. Trauma Stress</i> <b>5</b>, 377–391 (1992).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1002/jts.2490050305" data-track-action="article reference" href="https://doi.org/10.1002%2Fjts.2490050305" aria-label="Article reference 26" data-doi="10.1002/jts.2490050305">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Complex%20PTSD%3A%20a%20syndrome%20in%20survivors%20of%20prolonged%20and%20repeated%20trauma&amp;journal=J.%20Trauma%20Stress&amp;doi=10.1002%2Fjts.2490050305&amp;volume=5&amp;pages=377-391&amp;publication_year=1992&amp;author=Herman%2CJL">
                    Google Scholar</a> 
                </p></li><li data-counter="27."><p id="ref-CR27">Schein, J. et al. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. <i>Curr. Med Res. Opin.</i> <b>37</b>, 2151–2161 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/03007995.2021.1978417" data-track-action="article reference" href="https://doi.org/10.1080%2F03007995.2021.1978417" aria-label="Article reference 27" data-doi="10.1080/03007995.2021.1978417">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34498953" aria-label="PubMed reference 27">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Prevalence%20of%20post-traumatic%20stress%20disorder%20in%20the%20United%20States%3A%20a%20systematic%20literature%20review&amp;journal=Curr.%20Med%20Res.%20Opin.&amp;doi=10.1080%2F03007995.2021.1978417&amp;volume=37&amp;pages=2151-2161&amp;publication_year=2021&amp;author=Schein%2CJ">
                    Google Scholar</a> 
                </p></li><li data-counter="28."><p id="ref-CR28">Lewis-Schroeder, N. F. et al. Conceptualization, assessment, and treatment of traumatic stress in first responders: a review of critical issues. <i>Harv. Rev. Psychiatry</i> <b>26</b>, 216–227 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1097/HRP.0000000000000176" data-track-action="article reference" href="https://doi.org/10.1097%2FHRP.0000000000000176" aria-label="Article reference 28" data-doi="10.1097/HRP.0000000000000176">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29975339" aria-label="PubMed reference 28">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624844" aria-label="PubMed Central reference 28">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Conceptualization%2C%20assessment%2C%20and%20treatment%20of%20traumatic%20stress%20in%20first%20responders%3A%20a%20review%20of%20critical%20issues&amp;journal=Harv.%20Rev.%20Psychiatry&amp;doi=10.1097%2FHRP.0000000000000176&amp;volume=26&amp;pages=216-227&amp;publication_year=2018&amp;author=Lewis-Schroeder%2CNF">
                    Google Scholar</a> 
                </p></li><li data-counter="29."><p id="ref-CR29">Williams, C. P., Senft Everson, N., Shelburne, N. &amp; Norton, W. E. Demographic and health behavior factors associated with clinical trial invitation and participation in the United States. <i>JAMA Netw. Open</i> <b>4</b>, e2127792 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamanetworkopen.2021.27792" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamanetworkopen.2021.27792" aria-label="Article reference 29" data-doi="10.1001/jamanetworkopen.2021.27792">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34586365" aria-label="PubMed reference 29">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482053" aria-label="PubMed Central reference 29">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Demographic%20and%20health%20behavior%20factors%20associated%20with%20clinical%20trial%20invitation%20and%20participation%20in%20the%20United%20States&amp;journal=JAMA%20Netw.%20Open&amp;doi=10.1001%2Fjamanetworkopen.2021.27792&amp;volume=4&amp;publication_year=2021&amp;author=Williams%2CCP&amp;author=Senft%20Everson%2CN&amp;author=Shelburne%2CN&amp;author=Norton%2CWE">
                    Google Scholar</a> 
                </p></li><li data-counter="30."><p id="ref-CR30">Ching, T. H. et al. MDMA-assisted therapy for posttraumatic stress disorder: a pooled analysis of ethnoracial differences in efficacy and safety from two phase 2 open-label lead-in trials and a phase 3 randomized, blinded placebo-controlled trial. <i>J. Psychopharmacol.</i> <b>36</b>, 974–986 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/02698811221104052" data-track-action="article reference" href="https://doi.org/10.1177%2F02698811221104052" aria-label="Article reference 30" data-doi="10.1177/02698811221104052">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB38XitVKgsLfJ" aria-label="CAS reference 30">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35727042" aria-label="PubMed reference 30">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=MDMA-assisted%20therapy%20for%20posttraumatic%20stress%20disorder%3A%20a%20pooled%20analysis%20of%20ethnoracial%20differences%20in%20efficacy%20and%20safety%20from%20two%20phase%202%20open-label%20lead-in%20trials%20and%20a%20phase%203%20randomized%2C%20blinded%20placebo-controlled%20trial&amp;journal=J.%20Psychopharmacol.&amp;doi=10.1177%2F02698811221104052&amp;volume=36&amp;pages=974-986&amp;publication_year=2022&amp;author=Ching%2CTH">
                    Google Scholar</a> 
                </p></li><li data-counter="31."><p id="ref-CR31">Schnurr, P. P. et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: a randomized clinical trial. <i>JAMA Netw. Open</i> <b>5</b>, e2136921 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1001/jamanetworkopen.2021.36921" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamanetworkopen.2021.36921" aria-label="Article reference 31" data-doi="10.1001/jamanetworkopen.2021.36921">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35044471" aria-label="PubMed reference 31">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771295" aria-label="PubMed Central reference 31">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Comparison%20of%20prolonged%20exposure%20vs%20cognitive%20processing%20therapy%20for%20treatment%20of%20posttraumatic%20stress%20disorder%20among%20US%20veterans%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA%20Netw.%20Open&amp;doi=10.1001%2Fjamanetworkopen.2021.36921&amp;volume=5&amp;publication_year=2022&amp;author=Schnurr%2CPP">
                    Google Scholar</a> 
                </p></li><li data-counter="32."><p id="ref-CR32">Jerome, L. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. <i>Psychopharmacol. (Berl.)</i> <b>237</b>, 2485–2497 (2020).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1007/s00213-020-05548-2" data-track-action="article reference" href="https://doi.org/10.1007%2Fs00213-020-05548-2" aria-label="Article reference 32" data-doi="10.1007/s00213-020-05548-2">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtV2jsbvE" aria-label="CAS reference 32">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20follow-up%20outcomes%20of%20MDMA-assisted%20psychotherapy%20for%20treatment%20of%20PTSD%3A%20a%20longitudinal%20pooled%20analysis%20of%20six%20phase%202%20trials&amp;journal=Psychopharmacol.%20%28Berl.%29&amp;doi=10.1007%2Fs00213-020-05548-2&amp;volume=237&amp;pages=2485-2497&amp;publication_year=2020&amp;author=Jerome%2CL">
                    Google Scholar</a> 
                </p></li><li data-counter="33."><p id="ref-CR33">Lester, S. J. et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine: a double-blind, placebo-controlled trial. <i>Ann. Intern. Med.</i> <b>133</b>, 969–973 (2000).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.7326/0003-4819-133-12-200012190-00012" data-track-action="article reference" href="https://doi.org/10.7326%2F0003-4819-133-12-200012190-00012" aria-label="Article reference 33" data-doi="10.7326/0003-4819-133-12-200012190-00012">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BD3MXktFKktQ%3D%3D" aria-label="CAS reference 33">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11119398" aria-label="PubMed reference 33">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Cardiovascular%20effects%20of%203%2C4-methylenedioxymethamphetamine%3A%20a%20double-blind%2C%20placebo-controlled%20trial&amp;journal=Ann.%20Intern.%20Med.&amp;doi=10.7326%2F0003-4819-133-12-200012190-00012&amp;volume=133&amp;pages=969-973&amp;publication_year=2000&amp;author=Lester%2CSJ">
                    Google Scholar</a> 
                </p></li><li data-counter="34."><p id="ref-CR34">Vizeli, P. &amp; Liechti, M. E. Safety pharmacology of acute MDMA administration in healthy subjects. <i>J. Psychopharmacol.</i> <b>31</b>, 576–588 (2017).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1177/0269881117691569" data-track-action="article reference" href="https://doi.org/10.1177%2F0269881117691569" aria-label="Article reference 34" data-doi="10.1177/0269881117691569">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVyitro%3D" aria-label="CAS reference 34">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28443695" aria-label="PubMed reference 34">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20pharmacology%20of%20acute%20MDMA%20administration%20in%20healthy%20subjects&amp;journal=J.%20Psychopharmacol.&amp;doi=10.1177%2F0269881117691569&amp;volume=31&amp;pages=576-588&amp;publication_year=2017&amp;author=Vizeli%2CP&amp;author=Liechti%2CME">
                    Google Scholar</a> 
                </p></li><li data-counter="35."><p id="ref-CR35">Nicholas, C. R. et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. <i>Drug Alcohol Depend.</i> <b>233</b>, 109356 (2022).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.drugalcdep.2022.109356" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.drugalcdep.2022.109356" aria-label="Article reference 35" data-doi="10.1016/j.drugalcdep.2022.109356">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1KmsbfK" aria-label="CAS reference 35">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35286849" aria-label="PubMed reference 35">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750500" aria-label="PubMed Central reference 35">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20effects%20of%20MDMA-assisted%20therapy%20on%20alcohol%20and%20substance%20use%20in%20a%20phase%203%20trial%20for%20treatment%20of%20severe%20PTSD&amp;journal=Drug%20Alcohol%20Depend.&amp;doi=10.1016%2Fj.drugalcdep.2022.109356&amp;volume=233&amp;publication_year=2022&amp;author=Nicholas%2CCR">
                    Google Scholar</a> 
                </p></li><li data-counter="36."><p id="ref-CR36">Feduccia, A. A. et al. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. <i>Front. Psychiatry</i> <b>10</b>, 650 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.3389/fpsyt.2019.00650" data-track-action="article reference" href="https://doi.org/10.3389%2Ffpsyt.2019.00650" aria-label="Article reference 36" data-doi="10.3389/fpsyt.2019.00650">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31572236" aria-label="PubMed reference 36">PubMed</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751381" aria-label="PubMed Central reference 36">PubMed Central</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Breakthrough%20for%20trauma%20treatment%3A%20safety%20and%20efficacy%20of%20MDMA-assisted%20psychotherapy%20compared%20to%20paroxetine%20and%20sertraline&amp;journal=Front.%20Psychiatry&amp;doi=10.3389%2Ffpsyt.2019.00650&amp;volume=10&amp;publication_year=2019&amp;author=Feduccia%2CAA">
                    Google Scholar</a> 
                </p></li><li data-counter="37."><p id="ref-CR37">US Department of Veteran Affairs. PTSD: National Center for PTSD. Clinician’s guide to medications for PTSD (<a href="https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp" data-track="click" data-track-action="external reference" data-track-label="https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp">https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp</a>).</p></li><li data-counter="38."><p id="ref-CR38">Schenberg, E. E. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. <i>Expert Rev. Clin. Pharm.</i> <b>14</b>, 1317–1319 (2021).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/17512433.2021.1951473" data-track-action="article reference" href="https://doi.org/10.1080%2F17512433.2021.1951473" aria-label="Article reference 38" data-doi="10.1080/17512433.2021.1951473">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvVSkurrL" aria-label="CAS reference 38">CAS</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Who%20is%20blind%20in%20psychedelic%20research%3F%20Letter%20to%20the%20editor%20regarding%3A%20blinding%20and%20expectancy%20confounds%20in%20psychedelic%20randomized%20controlled%20trials&amp;journal=Expert%20Rev.%20Clin.%20Pharm.&amp;doi=10.1080%2F17512433.2021.1951473&amp;volume=14&amp;pages=1317-1319&amp;publication_year=2021&amp;author=Schenberg%2CEE">
                    Google Scholar</a> 
                </p></li><li data-counter="39."><p id="ref-CR39">Doblin, R. A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. <i>J. Psychoact. Drugs</i> <b>34</b>, 185–194 (2002).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1080/02791072.2002.10399952" data-track-action="article reference" href="https://doi.org/10.1080%2F02791072.2002.10399952" aria-label="Article reference 39" data-doi="10.1080/02791072.2002.10399952">Article</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20clinical%20plan%20for%20MDMA%20%28ecstasy%29%20in%20the%20treatment%20of%20posttraumatic%20stress%20disorder%20%28PTSD%29%3A%20partnering%20with%20the%20FDA&amp;journal=J.%20Psychoact.%20Drugs&amp;doi=10.1080%2F02791072.2002.10399952&amp;volume=34&amp;pages=185-194&amp;publication_year=2002&amp;author=Doblin%2CR">
                    Google Scholar</a> 
                </p></li><li data-counter="40."><p id="ref-CR40">Weathers, F. W. et al. <i>The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)</i> <a href="https://www.ptsd.va.gov/" data-track="click" data-track-action="external reference" data-track-label="https://www.ptsd.va.gov/">https://www.ptsd.va.gov/</a> (2013).</p></li><li data-counter="41."><p id="ref-CR41">Weathers, F. W. et al. The clinician administered PTSD scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. <i>Psychol. Assess.</i> <b>30</b>, 383–395 (2018).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1037/pas0000486" data-track-action="article reference" href="https://doi.org/10.1037%2Fpas0000486" aria-label="Article reference 41" data-doi="10.1037/pas0000486">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28493729" aria-label="PubMed reference 41">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20clinician%20administered%20PTSD%20scale%20for%20DSM-5%20%28CAPS-5%29%3A%20development%20and%20initial%20psychometric%20evaluation%20in%20military%20veterans&amp;journal=Psychol.%20Assess.&amp;doi=10.1037%2Fpas0000486&amp;volume=30&amp;pages=383-395&amp;publication_year=2018&amp;author=Weathers%2CFW">
                    Google Scholar</a> 
                </p></li><li data-counter="42."><p id="ref-CR42">Targum, S. D., Daly, E., Fedgchin, M., Cooper, K. &amp; Singh, J. B. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. <i>J. Psychiatr. Res</i> <b>111</b>, 68–73 (2019).</p><p><a data-track="click" rel="nofollow noopener" data-track-label="10.1016/j.jpsychires.2019.01.017" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jpsychires.2019.01.017" aria-label="Article reference 42" data-doi="10.1016/j.jpsychires.2019.01.017">Article</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="cas reference" href="https://jvns.ca/articles/cas-redirect/1:STN:280:DC%2BB3cjls1Cmsg%3D%3D" aria-label="CAS reference 42">CAS</a> 
    <a data-track="click" rel="nofollow noopener" data-track-label="link" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30685564" aria-label="PubMed reference 42">PubMed</a> 
    <a data-track="click" data-track-action="google scholar reference" data-track-label="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Comparability%20of%20blinded%20remote%20and%20site-based%20assessments%20of%20response%20to%20adjunctive%20esketamine%20or%20placebo%20nasal%20spray%20in%20patients%20with%20treatment%20resistant%20depression&amp;journal=J.%20Psychiatr.%20Res&amp;doi=10.1016%2Fj.jpsychires.2019.01.017&amp;volume=111&amp;pages=68-73&amp;publication_year=2019&amp;author=Targum%2CSD&amp;author=Daly%2CE&amp;author=Fedgchin%2CM&amp;author=Cooper%2CK&amp;author=Singh%2CJB">
                    Google Scholar</a> 
                </p></li></ol><p><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-023-02565-4?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div id="Ack1-section"><h2 id="Ack1">Acknowledgements</h2><div id="Ack1-content"><p>The authors thank all of the participants and their support networks. See the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="https://jvns.ca/articles/s41591-023-02565-4#MOESM1">Supplementary Information</a> for acknowledgments concerning study collaborators, including all members of the MAPP2 Study Collaborator Group.</p><p>This study was funded by Multidisciplinary Association for Psychedelic Studies (MAPS) with support from the Steven and Alexandra Cohen Foundation and organized by MAPS Public Benefit Corporation (PBC). MAPS PBC was responsible for overseeing the collection, analysis and interpretation of the data. Medical writing assistance was provided by J. Carpenter and M. Yochum of BOLDSCIENCE, funded by MAPS PBC.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div id="author-information-section"><h2 id="author-information">Author information</h2><div id="author-information-content"><p><span id="author-notes">Author notes</span></p><ol><li id="na2"><p>A list of members and their affiliations appears in the Supplementary Information.</p></li></ol><h3 id="affiliations">Authors and Affiliations</h3><ol><li id="Aff1"><p>Neuroscape, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA</p><p>Jennifer M. Mitchell</p></li><li id="Aff2"><p>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA</p><p>Jennifer M. Mitchell &amp; Sylvestre Quevedo</p></li><li id="Aff3"><p>Department of Veterans Affairs, Research Service, San Francisco VA Medical Center, San Francisco, CA, USA</p><p>Jennifer M. Mitchell</p></li><li id="Aff4"><p>Aguazul-Bluewater, Inc., Boulder, CO, USA</p><p>Marcela Ot’alora G.</p></li><li id="Aff5"><p>Boston University School of Medicine, Boston, MA, USA</p><p>Bessel van der Kolk</p></li><li id="Aff6"><p>Wholeness Center, Fort Collins, CO, USA</p><p>Scott Shannon</p></li><li id="Aff7"><p>Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA</p><p>Michael Bogenschutz</p></li><li id="Aff8"><p>Zen Therapeutic Solutions, Mt. Pleasant, SC, USA</p><p>Yevgeniy Gelfand</p></li><li id="Aff9"><p>Nautilus Sanctuary, New York, NY, USA</p><p>Casey Paleos</p></li><li id="Aff10"><p>Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA</p><p>Christopher R. Nicholas</p></li><li id="Aff11"><p>San Francisco Insight and Integration Center, San Francisco, CA, USA</p><p>Sylvestre Quevedo</p></li><li id="Aff12"><p>New School Research, LLC, Los Angeles, CA, USA</p><p>Brooke Balliett</p></li><li id="Aff13"><p>MAPS Public Benefit Corporation, San Jose, CA, USA</p><p>Scott Hamilton, Charlotte Harrison &amp; Berra Yazar-Klosinski</p></li><li id="Aff14"><p>Medical University of South Carolina, Charleston, SC, USA</p><p>Michael Mithoefer</p></li><li id="Aff15"><p>Kleiman Consulting and Psychological Services, PC, Ivyland, PA, USA</p><p>Sarah Kleiman</p></li><li id="Aff16"><p>KPG Psychological Services, LLC, Brunswick, ME, USA</p><p>Kelly Parker-Guilbert</p></li><li id="Aff17"><p>University of Haifa, Haifa, Israel</p><p>Keren Tzarfaty</p></li><li id="Aff18"><p>MAPS Israel, Hod Hasharon, Israel</p><p>Keren Tzarfaty</p></li><li id="Aff19"><p>Tulip Medical Consulting, LLC, Port Townsend, WA, USA</p><p>Alberdina de Boer</p></li><li id="Aff20"><p>Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA</p><p>Rick Doblin</p></li></ol><h3 id="groups">Consortia</h3><div id="group-1"><h3>MAPP2 Study Collaborator Group</h3><ul><li>Charlotte Harrison</li><li> &amp; Berra Yazar-Klosinski</li></ul></div><h3 id="contributions">Contributions</h3><p>S.H., B.Y.-K., C.H. and A.d.B. contributed to data analysis; these authors and J.M.M. directly accessed and collectively verified the underlying data. All authors had full access to the trial data, contributed to the interpretation of the data and contributed to writing the manuscript. The authors attest to the accuracy and completeness of the reported data, accept responsibility to submit for publication and confirm that the trial conformed to the protocol and the statistical analysis plan (available via <i>Nature Medicine</i>).</p><h3 id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:jennifer.mitchell@ucsf.edu">Jennifer M. Mitchell</a>.</p></div></div></section><section data-title="Ethics declarations"><div id="ethics-section"><h2 id="ethics">Ethics declarations</h2><div id="ethics-content">
            
              <h3 id="FPar2">Competing interests</h3>
              <p>J.M.M. has received research support from MAPS; grants/contracts from the Veterans Administration (Merit Award) and the FDA (Research Award); has received royalties/licenses from UCLA (for a patent licensed to UCSF for cell screening); has received payment/honoraria from Stanford (for lecturing to undergraduate students) and Johns Hopkins (for presenting grand rounds); has a patent licensed to UCSF for cell screening; has been a reviewer for NIAAA CTN; has been a member of CA DOJ RAP; and has been a grant reviewer for the Australian Medical Research Council. M.O.G.: Aguazul-Bluewater, Inc has received research support from MAPS PBC and payments from Cybin (training and consultation), from Horizons Conference and from Naropa University. B.v.d.K. has received royalties from Penguin Random House (book, <i>The Body Keeps the Score</i>) and Guilford Press (book, <i>Traumatic Stress</i>); has received consulting fees from Meadows Hospital (Wickenburg, Arizona); and has received payment/honoraria from PESI. B.v.d.K. is also the president of the Trauma Research Foundation. S.S. has received grants/contracts from MAPS (research support) and MindMed (research support); has received royalties/licenses from Academic Press and Norton Publishing (professional books); has received honoraria from Scripps, the Integrative Psychiatric Institute and the Institute of Functional Medicine (lectures and presentations); is member of the Maya Health Advisory Board; and previously served as CEO of the Board of Psychedelic Medicine and Therapies. M.B. has received grant support to his institution for the current study from MAPS PBC; has received grants/contracts to his institution from Mend Medicine, Tilray Canada and the Heffter Research Institute; has been paid by AJNA Labs, Journey Colab and Bright Minds Biosciences for advisory board participation; and has received drug to his institution from Tilray Canada for an NIH-funded trial. Y.G. anticipates support from MAPS PBC for congress attendance in the future and has stock in MindMed. C.P. has received grants/contracts (research support) and consulting fees from MAPS PBC (training and supervision/consultation). C.R.N. has received grants/contracts fromm MAPS PBC (research studies); has received payment/honoraria from MAPS PBC and MindMed (training and educational events); has received meeting/travel support from MAPS PBC; and has received funding for contract work as an MDMA-assisted therapy trainer. S.Q. has received grants/contract support for research from MAPS. B.B. has received support for the present study from New School Research and the California Center for Psychedelic Therapy; has received consulting fees from MAPS PBC (training and supervision/consultation); has received payment/honoraria from the Integrative Psychiatric Institute, the California Association of Marriage and Family Therapists, the Los Angeles County Psychological Society and the Palm Springs Art Museum (lectures/speaking events); has received support for meetings/travel from MAPS PBC; and is a trainer representative for the MAPS PBC Commercial Advisory Committee and supervisor and coordinator of the Zendo Project (psychedelic harm reduction). S.H. is an employee of MAPS PBC. M.M. has received support for the present research from MAPS PBC (independent contractor) and is a member of the Awakn Life Sciences Scientific Advisory Board; has received royalties from PESI (video sales of presentations); has received consulting fees from MAPS PBC; has received payment from PESI (speaking) and the California Institute of Integral Studies (training workshops); has received honoraria from Harvard Medical School, Sounds True, the Integrative Psychiatry Institute and Vital (speaking); has received support from MAPS PBC for attending meetings/travel; and owns stock in Awakn Life Sciences. S.K. has received grants/contracts/consulting fees from MAPS PBC, pharmaceutical companies, VA hospitals and university research groups for providing supervision and training to psychodiagnostic assessors on a variety of research studies. K.P.-G. has received consulting fees from MAPS PBC for training assessors in psychodiagnostic assessment on PTSD treatment trials and from other research studies/groups conducting similar work. K.T. has received payment/honoraria from MAPS US (education and study activities in Israel), MAPS PBC (senior trainer and supervisor therapist) and MAPS Israel (co-founder and CEO) and meeting/travel support from MAPS PBC. C.H. is a MAPS PBC employee; has received consulting fees from Cybin (unrelated molecule and indication in the psychedelics field); and has received meeting/travel support from MAPS PBC. A.d.B. was previously an employee of MAPS PBC; has received consulting fees (to Tulip Medical Consulting); has received meeting travel/support from MAPS PBC; and served as CMO (while previously an employee of MAPS PBC) and attended Data Safety Monitoring Board meetings without any voting rights. R.D. is the founder and president (salaried employee) of MAPS and is a member of the Board of MAPS and MAPS PBC. B.Y.-K. is an employee of MAPS PBC, was previously an employee of MAPS and has received support from MAPS PBC and MAPS for attending meetings/travel.</p>
            
          </div></div></section><section data-title="Peer review"><div id="peer-review-section"><h2 id="peer-review">Peer review</h2><div id="peer-review-content">
            
            
              <h3 id="FPar1">Peer review information</h3>
              <p><i>Nature Medicine</i> thanks Matthias Liechti, Alimu Dayimu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Jerome Staal, in collaboration with the <i>Nature Medicine</i> team.</p>
            
          </div></div></section><section data-title="Additional information"><div id="additional-information-section"><h2 id="additional-information">Additional information</h2><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></section><section data-title="Supplementary information"><div id="Sec19-section"><h2 id="Sec19">Supplementary information</h2><div id="Sec19-content"><div data-test="supplementary-info"><div data-test="supp-item" id="MOESM1"><h3><a data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-023-02565-4/MediaObjects/41591_2023_2565_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><p>CONSORT checklist, MAPP2 study collaborators, Supplementary Methods, Supplementary Figs. 1 and 2, Supplementary Tables 1–9 and Supplementary References.</p></div></div></div></div></section><section data-title="Source data"></section><section data-title="Rights and permissions"><div id="rightslink-section"><h2 id="rightslink">Rights and permissions</h2><div id="rightslink-content">
              <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
            <p><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=MDMA-assisted%20therapy%20for%20moderate%20to%20severe%20PTSD%3A%20a%20randomized%2C%20placebo-controlled%20phase%203%20trial&amp;author=Jennifer%20M.%20Mitchell%20et%20al&amp;contentID=10.1038%2Fs41591-023-02565-4&amp;copyright=This%20is%20a%20U.S.%20Government%20work%20and%20not%20under%20copyright%20protection%20in%20the%20US%3B%20foreign%20copyright%20protection%20may%20apply&amp;publication=1078-8956&amp;publicationDate=2023-09-14&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and Permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div id="article-info-section"><h2 id="article-info">About this article</h2><div id="article-info-content"><div><p><a data-crossmark="10.1038/s41591-023-02565-4" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-023-02565-4" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"/></a></p><div><h3 id="citeas">Cite this article</h3><p>Mitchell, J.M., Ot’alora G., M., van der Kolk, B. <i>et al.</i> MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
                    <i>Nat Med</i>  (2023). https://doi.org/10.1038/s41591-023-02565-4</p><p><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-023-02565-4?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use></svg></a></p><ul data-test="publication-history"><li><p>Received<span>: </span><span><time datetime="2023-06-02">02 June 2023</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime="2023-08-24">24 August 2023</time></span></p></li><li><p>Published<span>: </span><span><time datetime="2023-09-14">14 September 2023</time></span></p></li><li><p><abbr title="Digital Object Identifier">DOI</abbr><span>: </span><span>https://doi.org/10.1038/s41591-023-02565-4</span></p></li></ul></div></div></div></div></section>
            </div></div>
  </body>
</html>
